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Immunoreactivity;	 HOMA-R:	 Homeostasis	 Model	 Assessment-




The	 discussion	 concerning	 Calorie	 Restriction	 (CR)	 and	 low	
carbohydrate	 diet	 (LCD)	 has	 been	 continued	 for	 years.	 Several	




colleagues have lots of experience of LCD for T2DM, and reported 
clinical	 studies	 [7-10].	Our	 recent	 study	 includes	blood	glucose	
variability	 in	 diabetic	 patients,	 using	Morbus	 (M)	 value,	 which	






















HDL	/	HDL)	and	TG/HDL	value.	These	 results	would	 suggest	 that	RLP-C	may	be	
involved in the development of arteriosclerosis of T2DM, and may have the role 
of	further	research	direction	in	the	future.
In current study, our results would become the fundamental data for the further 
development	of	 LCD	 therapy	 in	 various	 counties	 and	districts,	 and	 suggest	 the	
research	direction	 for	patients	with	T2DM	from	the	combined	point	of	glucose	
and lipid metabolism in the future. 
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ranging between	28-84	years	old,	60.8	±	11.0	(mean	±	SD)	years	
old	 in	 average,	 63	 years	 old	 in	 the	 median	 value.	 They	 were	
admitted	for	14-15	days,	and	received	endocrine	and	metabolic	
evaluation	with	lipid	analysis.	
Methods	 included	 a	 controlled	 diet	 for	 the	 patients.	On	 day	 1	
and	 2,	 Calorie	 Restriction	 (CR)	 diet	 was	 provided	 which	 had	
60%	carbohydrates,	25%	lipids	and	15%	protein	with	1400	kcal/
day.	 From	day	3	 to	14	days,	 Low	Carbohydrate	Diet	 (LCD)	was	
provided,	 which	 had	 12%	 carbohydrates,	 64%	 lipids	 and	 24%	
protein	 with	 1400	 kcal/day.	 This	 has	 been	 called	 super-LCD	
formula	in	our	nutritional	investigation	for	LCD	[7,9,10,19].	
The	 examination	 protocol	 was	 as	 follows:	 1)	 basal	 biomarkers	
and	 daily	 profile	 of	 blood	 glucose	 on	 day	 2,	 2)	 daily	 profile	 of	
blood	glucose	on	day	4,	3)	several	biomarkers	such	as	triglyceride	
and uric acid on day 14.
Analysis method and M value
A	 daily	 profile	 of	 blood	 glucose	 was	measured	 7	 times	 a	 day,	





blood glucose from an arbitrary assigned “ideal” glucose value, 
with	an	expression	of	both	the	mean	glucose	value	and	the	effect	
of	glucose	swings	[11-14,20].
The	 formula	 of	 M	 value	 is	 as	 follows:	 M=MBS	 +	 MW,	 where	
MW=(maximum	blood	glucose	−	minimum	glucose)/20;	MBS=the	
mean	 of	 MBSBS;	 MBSBS=individual	 M-value	 for	 each	 blood	
glucose	value	 calculated	as	 (absolute	 value	of	 [10	×	 log	 (blood	
glucose	value/120)])	[3].
For	 the	 interpretation	of	M	value,	 the	 standard	 range	 is	 <180,	
borderline	 is	 180-320	 and	 abnormal	 is	 >320.	 There	 were	
discussions	concerning	how	many	times	of	 sampling	per	day	 is	
necessary.	It	was	reported	that	multiple	sampling	and	a	7-point	
glycemic trial per day would have yielded similar	results	[14,21].	
Statistical analyses
In	current	study,	data	was	represented	as	the	mean	±	standard	
deviation.	 For	 statistical	 analyses,	 correlation	 coefficients	
(Pearson)	were	 calculated	 using	 the	 JMP	 (Version	 8)	 statistical	
analysis	software	(JMP	Japan	Division	of	SAS	Institute	Japan	Ltd.,	
Minato-ku,	Tokyo,	Japan)	and	Microsoft	Excel	analytical	tool.





Current study was conducted in compliance with the ethical 
principles	of	the	Declaration	of	Helsinki	and	Japan’s	Act	on	the	








Summarized data of 121 subjects were shown in Table 1. They 
were categorized for 4 groups due to the average glucose level. 
The	 mean	 HbA1c	 in	 each	 group	 was	 6.3%,	 6.9%,	 7.9%,	 9.2%,	
respectively.	 Blood	 glucose	 level	 on	 day	 4	 was	 significantly	
decreased compared with those on day 2 in each group. 
Triglyceride	level	on	day	14	was	significantly	decreased	compared	
with those on day 2 in each group.
Correlation for HbA1c, glucose and M value
There were	 significant	 correlation	 between	 average	 glucose	
and HbA1c (Figure 1),	 and	 for	 the	 urinary	 C-peptide	 excretion	
between day 2 and 4 (Figure 2).
Average	glucose	on	day	2	and	4	revealed	significant	correlation	





4 decreased apparently. The change of M value in each group 
from day 2 to day 4 were shown in (Figure 5).
Analyses among lipid biomarkers
The change of TG levels from day 2 to day 14 were shown in 










Vol. 1 No. 1:04
3© Under License of Creative Commons Attribution 3.0 License 
Endocrinology Research and Metabolism
Categorization
group Group 1 Group 2 Group 3 Group 4
Subjects
number 30 30 30 31
sex	(male/female) 13/17 13/17 10/20 16/15
age	(y.o.) 60	(54-65) 64	(51-70) 65	(55-72) 64	(56-68)
average	glucose	(mg/dL) 123	(115-128) 161	(141-168) 198	(184-212) 259	(248-294)
Glucose (basal)
HbA1c	(%) 6.3	(5.9-7.1) 6.9	(6.3-7.4) 72	(7.4-9.1) 22	(8.5-10.2)
Fasting	Glucose	(mg/dL) 111	(102-135) 132	(118-141) 170	(151-205) 210	(186-235)
IRI	(µU/mL) 7.4	(6.0-12) 7.5	(3.9-10.4) 5.3	(3.6-10.1) 5.4	(3.1-7.8)
HOMA-R 2.4	(1.3-4.0) 2.4	(1.2-3.8) 2.1	(1.3-4.3) 23	(1.5-4.2)
HOMA-β 60	(30-85) 41	(24-58) 21	(11-40) 11	(7.7-17)
Glucose (M value related)
average	glucose	on	day	2	(mg/dL)	 123	(115-128) 161	(150-179) 198	(184-212) 259	(248-294)
average	glucose	on	day	4	(mg/dL) 101	(97-113) 125	(112-137) 152	(143-164) 185	(166-205)
M value on day 2 8.9	(5.7	-	21.7) 42.9	(33.1	-52.0) 120	(96.8	-	151) 325	(269	-	509)
M value on day 4 8.5	(4.2	-	14.8) 5.4	(3.2	-	9.5) 14.8	(7.6	-	28.1) 60.1	(32.8	-105)
Glucose (CPR excretion in urine) 
urinary	CPR	on	day	2	(mg/day) 67.3	(27.3-105) 56.5	(36.5-86.8) 59.4	(38.5-66.2) 74.0	(50.5-89.7)
urinary	CPR	on	day	4	(mg/day) 56.0	(34.1-73.0) 40.8	(25.5-52.1) 43.3	(33.8-83.4) 64.0	(51.0-73.0)
Lipid Metabolism
Triglyceride	on	day	2		(mg/dL) 113	(71-143) 94	(67.5-157) 96	(73.5-125) 114	(70-175)
Triglyceride	on	day	14		(mg/dL) 93	(59-111) 88	(61.5-99) 69	(56-89) 88	(71-113)
HDL-C	on	day	2		(mg/dL) 57	(49-72) 57	(48-68) 65	(58.3-76) 63	(53-89)
HDL-C	on	day	14		(mg/dL) 47.5	(42-68) 50	(44-62) 58	(52-74)	 59	(46-70)
LDL-C	on	day	2		(mg/dL) 109	(97-137) 132	(102-1551) 126	(104-158) 145	(103-171)
LDL-C	on	day	14		(mg/dL) 120	(110-141) 138	(115-175) 137	(113-160) 155	(114-180)
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Figure 2 Correlation	 of	 urinary	 C-peptide	 excretion	 between	
day 2 and 4. CR diet was provided on day 1 and 2, and 
LCD	was	provided	from	day	3	to	14.	Urinary	C-peptide	
excretion	was	measured	for	24	hours	during	the	formula	
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Comparison of average glucose and M value between CR and LCD. A) Average 
glucose	on	day	2	and	4	revealed	significant	correlation	(p<0.01)	and	glucose	level	
decreased	according	to	the	regression	curve	(y	=	0.5765x	+	36.36).	B) M value on day 
2	and	4	revealed	significant	correlation	(p<0.01)	and	M	value	decreased	according	
to	the	regression	curve	(y	=	0.2873x	-	8.3151).
Figure 4 Correlation	of	average	glucose	and	M	value	on	CR	and	LCD.	A) Average glucose and
M	value	on	day	2	revealed	significant	correlation	(p<0.01).	B) Similarly, both factors 
had	significant	correlation	(p<0.01).	Compared	with	both	figures,	average	glucose	
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Figure 5 The change of M value in each group from day 2 to day 4. A) Group 1 revealed almost 
same median value, and group 2 revealed decreased median values. B) Group 3 and 4 
revealed	decreased	median	levels	from	day	2	to	day	4.	Boxplot	shows	5	components,	
which	are	median.	25%	quartile,	75%	quartile,	maximum	and	minimum.	
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research	 for	years	 [1-6,22-25].	 In	 Japan,	author	and	colleagues	




which	 is	 equivalent	 to	 VLCKD.	Our	 formula	 diet	 contains	 1400	
kcal/day,	which	has	168	kcal	of	carbohydrate	(1400	kcal	×	0.12),	








Average	 blood	 glucose	 in	 4	 groups	 decreased,	 indicating	 the	
short	 effect	 of	 LCD	 only	 for	 2	 days	 from	 CR	 to	 LCD.	 M	 value	
also	 significantly	 decreased	 in	 group	 2,3	 and	 4.	 M	 value	 is	
characterized for its larger numerical change than that of glucose, 
and	for	better	evaluation	of	relieving	status.	On	contrast,	M	value	
in group 1 was not so changed from day 2 to 4, which seemed 
to	be	 the	 characteristic	point	of	M	value.	 If	 the	average	blood	
glucose	decrease	 from	100	mg/dl	 to	80	mg/dL,	M	value	would	
increase because M value becomes minimum level when blood 
glucose	is	100	mg/dL.	
For	 only	 2	 days of formular LCD, there were considerable 
decrease	 of	 average	 glucose,	 urinary	 C-peptide	 excretion	 and	
M	 value.	 Obtained	 linear	 regression	 curve	 would	 become	 the	
reference	data	for	this	area	of	research.	The	decrease	ratio	of	M	
value is larger than that of glucose, because M value represents 
both	average	glucose	and	MAGE.	
Recently,	 the	 research	 of	 LCD	 have	 focused	 to	 less	 influence	
to	 cardiovascular	 risk	 factors,	 and	 research	 the	 relationship	
between	glucose	and	lipids	metabolism	[31-33].	
Isolation	 of	 remnant-like	 particles	 (RLPs)	 was	 performed	 and	
investigated,	 which	 are	 thought	 to	 be	 atherogenic	 agent	 [15].	
RLP-C	was	 supposed	 to	 be	 an	 independent	 risk	 factor	 for	 CVD	
in	women,	and	provides	significantly	more	information	than	do	
triglycerides	[16,34].	After	that,	Epidemiologic	studies	have	shown	
associations	 between	 RLP	 concentrations	 and	 atherosclerosis,	
cardiovascular	 disease	 (CVD),	 and	 chronic	 heart	 disease	 (CHD)	
[17,35].	
Elevated	 RLP-C	 were	 observed	 in	 T2DM	 [16,34,36].	 Diabetes	
Atherosclerosis	 Intervention	 Study	 (DAIS)	 had	measured	 RLP-C	
and	 TG	 levels,	 which	were	 significantly	 higher	 in	 diabetic	 CAD	
group	than	non-diabetic	CAD	group	[37].	Furthermore,	The	AUCs	
of	 TG	or	 RLP-C	 showed	 a	 correlation	with	 the	AUCs	of	 plasma	
insulin,	 with	 the	 correlation	 with	 the	 insulin	 resistance	 index	
[37,38].	
In	metabolic	 syndrome,	 obesity	 and	 insulin	 resistance,	 ratio	of	









high	value	of	 triglyceride	would	not	be	adequate	 for	 statistical	
analyses.	For	future	study,	we	will	analyze	those	patients	in	the	
combined research of glucose and lipid metabolism. 




Different	 dietary	 approaches	 on	 glycemic	 control	 has	 been	














• Current study would become fundamental data for the
field	 of	 T2DM,	 LCD	 and	 research	 direction	 for	 glucose/
lipid metabolism in the future.
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